Licenses product-candidate rights to partners and sells ZEVASKYN, a gene-modified cell therapy for wounds caused by a rare inherited skin disease, to qualified treatment centers.
10-K for FY2025, filed Mar 17, 2026Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a…View ↗
The Company enters into license agreements that are within the scope of ASC 606, under which it may exclusively license rights to research…View ↗
The Company generates revenue from sales in the United States of its commercially approved ZEVASKYN®. The Company’s customers for ZEVASKYN®…View ↗
Licensing partners pay for product-candidate rights through upfront fees, reimbursements, option or milestone payments, and royalties; qualified treatment centers pay for ZEVASKYN after its final quality inspection.
10-K for FY2025, filed Mar 17, 2026
10-K for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗$5.8M
10-K for FY2025, filed Mar 17, 2026
$5.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 17, 2026 |
42% |
Product, FY2025
$2.4M Sources
|
Sold outright |
|
License
Licensed
10-K for FY2025, filed Mar 17, 2026 |
58% |
License, FY2025
$3.4M Sources
|
Licensed |
Qualified treatment centers buy ZEVASKYN directly from Abeona under approved agreements. Third-party partners license rights to research, develop, manufacture, and commercialize product candidates.
10-K for FY2025, filed Mar 17, 2026
10-K for FY2025, filed Mar 17, 2026
For the year ended and as of December 31, 2025 % of Revenue % of Accounts Receivable Customer 1 48.1 % 51.2 % Customer 2 45.8 % 48.8 %View ↗
Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$84.3M.
8-K, filed Nov 9, 2026
CLEVELAND, November 9, 2026 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the acquisition of APT-1011 (now ABO-801), a product…View ↗
Growing. Revenue grew 94% in 4 years, from $3M in FY2021 to $5.8M in FY2025, about 18% a year.
RDEB therapy commercialization
The RDEB therapy moved from clinical development to commercialization: the older report describes the therapy in development, while the latest describes the approved product being commercialized for RDEB wounds.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 17, 2026Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a…View ↗
Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a…View ↗
Through our cell and gene therapy expertise in research and development, we believe we are positioned to introduce efficacious and safe…View ↗
On April 28, 2025, the FDA approved ZEVASKYN® as the first and only autologous cell-based gene therapy for the treatment of wounds in adult…View ↗
Loading...